Nitric oxide dysregulation in platelets from patients with advanced Huntington disease

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Carrizzo, Albino ^a   Di Pardo, Alba ^a   Maglione, Vittorio ^a   Damato, Antonio ^a   Amico, Enrico ^a   Formisano, Luigi ^b   Vecchione, Carmine ^a,c   Squitieri, Ferdinando ^a  

^a IRCCS NEUROMED   (Italy)

^b UNIVERSITY OF SANNIO   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; INSULIN; NITRIC OXIDE; NOS3 PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; SIGNAL TRANSDUCTION; THROMBOCYTE; VASODILATATION; ANALYSIS OF VARIANCE; CASE CONTROL STUDY; IMMUNOBLOTTING; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

ANALYSIS OF VARIANCE; BLOOD PLATELETS; CASE-CONTROL STUDIES; FEMALE; HUMANS; HUNTINGTON DISEASE; IMMUNOBLOTTING; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; SIGNAL TRANSDUCTION; VASODILATION;

EID: 84896109905     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089745     Document Type: Article

References (34)

1. Roos RA (2010) Huntington's disease: a clinical review. Orphanet J Rare Dis 5: 40.
2. Sugars KL, Rubinsztein DC (2003) Transcriptional abnormalities in Huntington disease. Trends Genet 19: 233-238. (Pubitemid 36511427)
3. van der Burg JM, Bjorkqvist M, Brundin P (2009) Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol 8: 765-774.
4. Sassone J, Colciago C, Cislaghi G, Silani V, Ciammola A (2009) Huntington's disease: the current state of research with peripheral tissues. Exp Neurol 219: 385-397.
5. Maglione V, Giallonardo P, Cannella M, Martino T, Frati L, et al. (2005) Adenosine A2A receptor dysfunction correlates with age at onset anticipation in blood platelets of subjects with Huntington's disease. Am J Med Genet B Neuropsychiatr Genet 139B: 101-105. (Pubitemid 41552306)
6. Maglione V, Cannella M, Martino T, De Blasi A, Frati L, et al. (2006) The platelet maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion in Huntington's disease patients with predominant chorea. Neurosci Lett 393: 27-30. (Pubitemid 41739648)
7. Deckel AW, Gordinier A, Nuttal D, Tang V, Kuwada C, et al. (2001) Reduced activity and protein expression of NOS in R6/2 HD transgenic mice: effects of L-NAME on symptom progression. Brain Res 919: 70-81. (Pubitemid 33016591)
8. Puca AA, Carrizzo A, Ferrario A, Villa F, Vecchione C (2012) Endothelial nitric oxide synthase, vascular integrity and human exceptional longevity. Immun Ageing 9: 26.
9. Forstermann U, Sessa WC (2012) Nitric oxide synthases: regulation and function. European Heart Journal 33: 829-837, 837a-837d.
10. Mount PF, Kemp BE, Power DA (2007) Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J Mol Cell Cardiol 42: 271-279. (Pubitemid 46135596)
11. Calabrese V, Bates TE, Stella AM (2000) NO synthase and NO-dependent signal pathways in brain aging and neurodegenerative disorders: the role of oxidant/antioxidant balance. Neurochem Res 25: 1315-1341.
12. Schulz JB, Matthews RT, Beal MF (1995) Role of nitric oxide in neurodegenerative diseases. Curr Opin Neurol 8: 480-486. (Pubitemid 26039809)
13. Perez-Severiano F, Escalante B, Vergara P, Rios C, Segovia J (2002) Age-dependent changes in nitric oxide synthase activity and protein expression in striata of mice transgenic for the Huntington's disease mutation. Brain Res 951: 36-42. (Pubitemid 35253894)
14. Dukart J, Schroeter ML, Mueller K (2011) Age correction in dementia - matching to a healthy brain. PLoS One 6: e22193.
15. (1996) Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord 11: 136-142.
16. Marder K, Sandler S, Lechich A, Klager J, Albert SM (2002) Relationship between CAG repeat length and late-stage outcomes in Huntington's disease. Neurology 59: 1622-1624. (Pubitemid 35387072)
17. (1991) Declaration of Helsinki. Law Med Health Care 19: 264-265.
18. Gentile MT, Vecchione C, Marino G, Aretini A, Di Pardo A, et al. (2008) Resistin impairs insulin-evoked vasodilation. Diabetes 57: 577-583.
19. Vecchione C, Brandes RP (2002) Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ Res 91: 173-179. (Pubitemid 34827229)
20. Carrizzo A, Puca A, Damato A, Marino M, Franco E, et al. (2013) Resveratrol improves vascular function in patients with hypertension and dyslipidemia by modulating NO metabolism. Hypertension 62: 359-366.
21. Radomski M, Moncada S (1983) An improved method for washing of human platelets with prostacyclin. Thromb Res 30: 383-389. (Pubitemid 13053477)
22. Ku CJ, Karunarathne W, Kenyon S, Root P, Spence D (2007) Fluorescence determination of nitric oxide production in stimulated and activated platelets. Anal Chem 79: 2421-2426. (Pubitemid 46449023)
23. Squitieri F, Maglione V, Orobello S, Fornai F (2011) Genotype-, aging-dependent abnormal caspase activity in Huntington disease blood cells. J Neural Transm 118: 1599-1607.
24. Runne H, Kuhn A, Wild EJ, Pratyaksha W, Kristiansen M, et al. (2007) Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood. Proc Natl Acad Sci U S A 104: 14424-14429. (Pubitemid 350003277)
25. Markianos M, Panas M, Kalfakis N, Vassilopoulos D (2004) Platelet monoamine oxidase activity in subjects tested for Huntington's disease gene mutation. J Neural Transm 111: 475-483. (Pubitemid 38478915)
26. Muramatsu Y, Kaiya H, Imai H, Nozaki M, Fujimura H, et al. (1982) Abnormal platelet aggregation response in Huntington's disease. Arch Psychiatr Nervenkr 232: 191-200. (Pubitemid 13211559)
27. Deckel AW, Tang V, Nuttal D, Gary K, Elder R (2002) Altered neuronal nitric oxide synthase expression contributes to disease progression in Huntington's disease transgenic mice. Brain Res 939: 76-86. (Pubitemid 34518591)
28. Deckel AW (2001) Nitric oxide and nitric oxide synthase in Huntington's disease. J Neurosci Res 64: 99-107.
29. Loscalzo J (2001) Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 88: 756-762.
30. Kiriazis H, Jennings NL, Davern P, Lambert G, Su YD, et al. (2012) Neurocardiac dysregulation and neurogenic arrhythmias in a transgenic mouse model of Huntington's disease. Journal of Physiology-London 590: 5845-5860.
31. Mihm MJ, Amann DM, Schanbacher BL, Altschuld RA, Bauer JA, et al. (2007) Cardiac dysfunction in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 25: 297-308. (Pubitemid 46127844)
32. Barton M, Cosentino F, Brandes RP, Moreau P, Shaw S, et al. (1997) Anatomic heterogeneity of vascular aging: role of nitric oxide and endothelin. Hypertension 30: 817-824. (Pubitemid 27441107)
33. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, et al. (1999) Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399: 597-601.
34. Reynolds NC Jr, Hellman RS, Tikofsky RS, Prost RW, Mark LP, et al. (2002) Single photon emission computerized tomography (SPECT) in detecting neurodegeneration in Huntington's disease. Nucl Med Commun 23: 13-18. (Pubitemid 34214302)